Drug and Alcohol Dependence
Volume 111, Issue 1 , Pages 30-37 , 1 September 2010

Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users

  • Vince Cakic

      Affiliations

    • School of Psychology, University of Sydney, Sydney, NSW 2006, Australia
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jacob Potkonyak

      Affiliations

    • School of Psychology, Macquarie University, Sydney, NSW 2109, Australia
    • ,
  • Alex Marshall

      Affiliations

    • School of Psychology, University of Sydney, Sydney, NSW 2006, Australia

Received 16 February 2010 ,Revised 7 March 2010 ,Accepted 9 March 2010.

References 

  1. Andrews JA, Tildesley E, Hops H, Li F. The influence of peers on young adult substance use. Health Psychol. 2002;21:349–357
  2. Barker SA, Monti JA, Christian ST. N,N-dimethyltryptamine: an endogenous hallucinogen. Int. Rev. Neurobiol. 1981;22:83–110
  3. Biernacki P, Waldorf D. Snowball sampling: problems and techniques of chain referral sampling. Sociol. Methods Res. 1981;10:141–163
  4. Boyer EW, Shannon M, Hibberd PL. The Internet and psychoactive substance use among innovative drug users. Pediatrics. 2005;115:302–305
  5. Bullis RK. The “vine of the soul” vs. the Controlled Substances Act: implications of the Hoasca case. J. Pschoactive Drugs. 2008;40:193–199
  6. Bunzow JR, Sonders MS, Arttmangkul S, Harrison LM, Zhang G, Quigley DI, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 2001;60:1181–1188
  7. Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J. Psychoactive Drugs. 1998;30:367–369
  8. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. J. Ethnopharmacol. 1999;65:243–256
  9. Cox, N., 2009. Police seize killer new drug. http://www.theaustralian.news.com.au/story/0,24751058-5006789,00.html (accessed 12.02.10).
  10. Da Silveira DX, Grob CS, Dobkin de Rios M, Lopez E, Alonson LK, Tacla C, et al. Ayahuasca in adolescence: a preliminary psychiatric assessment. J. Psychoactive Drugs. 2005;37:129–133
  11. Dalgarno P. Buying ayahuasca and other entheogens online: a word of caution. Addict. Res. Theory. 2008;16:1–4
  12. De Conceicao, P., 2009. The DMT molecule: A tryst with spirits, elves and aliens. http://www.examiner.com/x-17195-LA-Esoteric-History-Examiner∼y2009m8d6-The-DMT-molecule-A-tryst-with-spirits-elves-and-aliens (accessed 15.05.10).
  13. Dobkin de Rios M. Visionary Vine: Hallucinogenic Healing in the Peruvian Amazon. San Francisco: Chandler Publishing; 1972;
  14. Doering-Silveira E, Grob CS, Dobkin de Rios M, Lopez E, Alonso LK, Tacla C, et al. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J. Psychoactive Drugs. 2005;37:141–144
  15. Doering-Silveira E, Lopez E, Grob CS, Dobkin de Rios M, Alonson LK, Tacla C, et al. Ayahuasca in adolescence: a neuropsychological assessment. J. Psychoactive Drugs. 2005;37:123–128
  16. Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D. Gender differences in the initiation of injection drug use among young adults. J. Urban Health. 2000;77:396–414
  17. Faillace LA, Szára S. Hallucinogenic drugs: influence of mental set and setting. Dis. Nerv. Syst. 1968;29:124–126
  18. Fitzgerald JS, Sioumis AA. Alkaloids of the Australian Leguminosae: V. The occurrence of methylated tryptamines in Acacia maidenii. Aust. J. Chem. 1965;18:433–434
  19. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323:934–937
  20. Forsyth AJM. Places and patterns of drug use in the Scottish dance scene. Addiction. 1996;91:511–521
  21. Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction. 2007;102:24–34
  22. Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend. 2006;85:157–162
  23. Greenhouse, L., 2006. Sect allowed to import its hallucinogenic tea. http://www.nytimes.com/2006/02/22/politics/22scotus.html (accessed 15.05.10).
  24. Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol. 2008;22:621–632
  25. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268–283
  26. Grigoriadis, V., 2006. Daniel Pinchbeck and the new psychedelic elite. http://www.rollingstone.com/politics/story/11217201/daniel_pinchbeck_and_the_new_psychedelic_elite (accessed 12.02.10).
  27. Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J. Nerv. Ment. Dis. 1996;184:86–94
  28. Grof S. LSD Psychotherapy. Ben Lonmond: MAPS; 2008;
  29. Halpern JH, Pope HG. Hallucinogens on the internet: a vast new source of underground drug information. Am. J. Psychiatry. 2001;158:481–483
  30. Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med. Sci. Monit. 2008;14:S15–S22
  31. Hofmann A. LSD: My Problem Child. Sarasota, FL: MAPS; 2005;
  32. Kandel DB, Kessler RC, Margulies RZ. Antecedents of adolescent initiation into stages of drug use: a developmental analysis. J. Youth Adolesc. 1978;7:13–40
  33. Lange JE, Reed MB, Croff JMK, Clapp JD. College student use of Salvia divinorum. Drug Alcohol Depend. 2008;94:263–266
  34. Luckman S. Going bush and finding one's ‘tribe’: raving, escape and the bush doof. Continuum: J. Media Cult. Stud. 2003;17:315–330
  35. MacRae E. Santo Daime and Santa Maria—the licit ritual use of ayahuasca and the illicit use of cannabis in a Brazilian Amazonian religion. Int. J. Drug Policy. 1998;9:325–338
  36. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol. Ther. 2004;102:111–129
  37. McKenna DJ. Ayahuasca: an ethnopharmacologic history. In:  Metzner R editors. Sacred Vine of Spirits: Ayahuasca. Rochester, Vermont: Park Street Press; 2006;
  38. Otis, J., 2009. Down the Amazon in search of ayahuasca. http://www.time.com/time/world/article/0,8599,1889631,00.html (accessed 15.05.10).
  39. Ott J. Pharmacoetheon: Entheogenic Drugs, Their Plant Sources and History. Kennewick, WA: Natural Products Co.; 1996;
  40. Pomilio AB, Vitale AA, Ciprian-Ollivier J, Cetkovich-Bakmas M, Gómez R, Vazquez G. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia. J. Ethnopharmacol. 1999;65:29–51
  41. Room R. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev. 2005;24:143–155
  42. Rothlin E. Pharmacology of lysergic acid diethylamide (LSD) and some of its related compounds. In:  Garattini S,  Ghetti V editor. Psychotropic Drugs. New York: Elsevier; 1957;p. 36–47
  43. Rouvelli B, Vaughan GN. Alkaloids of Acacia I. Nb–Nb-dimethyltryptamine in Acacia phlebophylla. Aust. J. Chem. 1967;20:1299–1300
  44. Shanon B. The Antipodes of the Mind: Charting the Phenomenology of the Ayahuasca Experience. New York: Oxford University Press; 2002;
  45. Shulgin A, Shulgin A. Phenethylamines and I have Known and Loved: A Chemical Love Story. Berkley, CA: Transform Press; 1991;
  46. Shulgin A, Shulgin A. Tryptamines I have Known and Loved: The Continuation. Berkley, CA: Transform Press; 1997;
  47. Smith RL, Canton H, Barrett RJ, Sanders-Bush E. Agonst properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol. Biochem. Behav. 1998;61:323–330
  48. Strassman RJ. DMT: The Spirit Molecule. Rochester, Vermont: Park Street Press; 2001;
  49. Swift W, Copeland J, Hall W. Choosing a diagnostic cut-off for cannabis dependence. Addiction. 1998;93:1681–1692
  50. Szára S. Dimethyltryptamin: its metabolism in man; the relation of its psychotic effect to the serotonin metabolism. Cell. Mol. Life Sci. 1956;12:441–442
  51. Thompson SK, Collins LM. Adaptive sampling in research on risk-related behaviors. Drug Alcohol Depend. 2002;68:S57–67
  52. Tramacchi D. Field tripping: psychedelic communitas and ritual in the Australian bush. J. Contemp Rel. 2000;15:201–213
  53. Tramacchi, D., 2006. Vapours and visions: Religious dimensions of DMT use. School of History, Philosophy, Religion and Classics. University of Queensland, Brisbane.
  54. Trichter S, Klimo J, Krippner S. Changes in spirituality among ayahuasca ceremony novice participants. J. Psychoactive Drugs. 2009;41:121–134
  55. Tupper KW. Ayahuasca healing beyond the Amazon: the globalization of a traditional indigenous entheogenic practice. Global Netw. 2009;9:117–136
  56. Tupper KW. The globalization of ayahuasca: harm reduction or benefit maximisation?. Int. J. Drug Policy. 2008;19:297–303
  57. Turner DM. The Essential Psychedelic Handbook. San Francisco: Panther Press; 1994;
  58. Wilkinson DA, Leigh GM, Cordingley J, Martin GW, Lei H. Dimensions of multuple drug use and a typology of drug users. Br. J. Addict. 1987;82:259–273

PII: S0376-8716(10)00134-1

doi: 10.1016/j.drugalcdep.2010.03.015

Drug and Alcohol Dependence
Volume 111, Issue 1 , Pages 30-37 , 1 September 2010

Article Tools